Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron + Dexamethasone for CINV Prevention
NCT00687011Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co. Primary endpoint: Proportion of patients having achieved complete response (CR) at 24 hours. Started Oct 2006; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00687011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00687011.